Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Low-molecular-weight heparin as thromboprophylaxis in pregnancy

Saskia Middeldorp • 10 Dec 2022
ASH 2022
Rare Diseases Heparin
ALIFE ALIFE2 Highlow

Saskia Middeldorp, MD, PhD, Radboud University Medical Center, Nijmegen, Netherlands, discusses the role of intermediate-dose low-molecular-weight heparin as thromboprophylaxis in pregnant women with venous thromboembolism, and the importance of conducting further clinical trials in this space. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Bayer: Honoraria; Pfizer: Honoraria, Research Funding; Boehringer Ingelheim: Honoraria, Research Funding; Abbvie: Honoraria; Viatris: Honoraria; Sanofi: Honoraria; Norgine: Honoraria; GSK: Honoraria; Daiichi Sankyo: Honoraria, Research Funding; Astra Zeneca: Honoraria.

More from Saskia Middeldorp

ASH 2022 LBA: Findings from the ALIFE2 trial
1:48
ASH 2022 LBA: Findings from the ALIFE2 trial
Saskia Middeldorp • 10 Dec 2022

Related Videos

LENAZART: lenalidomide, oral azacitidine, & radiotherapy in newly diagnosed & relapsed plasmacytoma
3:31
LENAZART: lenalidomide, oral azacitidine, & radiotherapy in newly diagnosed & relapsed plasmacytoma
Urvi Shah • 25 Sep 2026
BPDCN: unmet needs, CD123-targeted therapies and novel targets
15:50
BPDCN: unmet needs, CD123-targeted therapies and novel targets
Naveen Pemmaraju • 19 Sep 2026
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
2:19
Phase III CARES: survival and cardiovascular outcomes with anselamimab in cardiac AL amyloidosis
Ashutosh Wechalekar • 9 Sep 2026
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
1:39
Managing solitary plasmacytomas: importance of accurate imaging and bone marrow assessment
Elena Zamagni • 25 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals